Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB35 and SCTB41 in Non-Hodgkin's Lymphoma
NCT07819188Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, single-arm trial of SCTB35 and SCTB41 in non-Hodgkin lymphoma (NHL), sponsored by Sinocelltech Group Limited. Primary endpoints: Dose-Limiting Toxicity at 28 days and Objective Response Rate at 3 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SCTB35SCTB41
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07819188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819188.